In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system

References

• Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H et al. (1995). Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol, 285:181–188.
   PubMed Web of Science ®Google Scholar
• Warner GT, Jarvis B. (2002). Olmesartan medoxomil. Drugs, 62:1345–1353.
   PubMed Web of Science ®Google Scholar
• Neutel JM, Elliott WJ, Izzo JL, Chen CL, Masonson HN. (2002). Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens (Greenwich), 4:325–331.
   PubMedGoogle Scholar
• Koike H. (2001). New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol, 87:33C–36C.
   PubMed Web of Science ®Google Scholar
• Mizuno M, Sada T, Kato M, Koike H. (2002). Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res, 25:271–278.
   PubMed Web of Science ®Google Scholar
• Kurikawa N, Suga M, Kuroda S, Yamada K, Ishikawa H. (2003). An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol, 139:1085–1094.
   PubMed Web of Science ®Google Scholar
• Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T et al. (2006). OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos, 34:862–869.
   PubMed Web of Science ®Google Scholar
• Neutel JM. (2001). Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol, 87:37C–43C.
   PubMed Web of Science ®Google Scholar
• Schwocho LR, Masonson HN. (2001). Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol, 41:515–527.
   PubMed Web of Science ®Google Scholar
• Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y et al. (2007). Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos, 35:2166–2176.
   PubMed Web of Science ®Google Scholar
• Shah NH, Carvajal MT, Patel CI, Infield MH, Malick AW. (1994). Self-emulsifying drug delivery systems (SEDDS) with polyglycolized glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm, 106:15–23.
   Web of Science ®Google Scholar
• Gursoy RN, Benita S. (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother, 58:173–182.
   PubMed Web of Science ®Google Scholar
• Humberstone AJ, Charman WN. (1997). Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev, 25:103–128.
   Web of Science ®Google Scholar
• Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. (2004). Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm, 278:119–131.
   PubMed Web of Science ®Google Scholar
• Lee BS, Kang MJ, Choi WS, Choi YB, Kim HS, Lee SK et al. (2009). Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability. Arch Pharm Res, 32:1629–1635.
   PubMed Web of Science ®Google Scholar
• Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A et al. (1999). Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res, 16:1812–1817.
   PubMed Web of Science ®Google Scholar
• Fagerholm U, Johansson M, Lennernäs H. (1996). Comparison between permeability coefficients in rat and human jejunum. Pharm Res, 13:1336–1342.
   PubMed Web of Science ®Google Scholar
• Högerle ML, Winne D. (1983). Drug absorption by the rat jejunum perfused in situ. Dissociation from the pH-partition theory and role of microclimate-pH and unstirred layer. Naunyn Schmiedebergs Arch Pharmacol, 322:249–255.
   PubMed Web of Science ®Google Scholar
• Sutton SC, Rinaldi MT, Vukovinsky KE. (2001). Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model. AAPS PharmSci, 3:E25.
   PubMedGoogle Scholar
• Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Azarmi Y, Islambolchilar Z, Barzegar S et al. (2007). Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci, 10:368–379.
   PubMed Web of Science ®Google Scholar
• Zhang P, Liu Y, Feng N, Xu J. (2008). Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm, 355:269–276.
   PubMed Web of Science ®Google Scholar
• Khoo SM, Humberstone AJ, Porter CJ, Edwards GA, Charman WN. (1998). Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm, 167:155–164.
   Web of Science ®Google Scholar
• Berggren S, Hoogstraate J, Fagerholm U, Lennernäs H. (2004). Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. Eur J Pharm Sci, 21:553–560.
   PubMed Web of Science ®Google Scholar
• Komiya I, Park JY, Kamani A, Ho NFH, Higuchi WI. (1980). Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes. Int J Pharm, 4:249–262.
   Web of Science ®Google Scholar
• Levitt MD, Kneip JM, Levitt DG. (1988). Use of laminar flow and unstirred layer models to predict intestinal absorption in the rat. J Clin Invest, 81:1365–1369.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Panchagnula R. (2005). Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. Biopharm Drug Dispos, 26:321–334.
   PubMed Web of Science ®Google Scholar
• Cook TJ, Shenoy SS. (2003). Intestinal permeability of chlorpyrifos using the single-pass intestinal perfusion method in the rat. Toxicology, 184:125–133.
   PubMed Web of Science ®Google Scholar
• Tian R, Koyabu N, Takanaga H, Matsuo H, Ohtani H, Sawada Y. (2002). Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res, 19:802–809.
   PubMed Web of Science ®Google Scholar
• Tarr BD, Yalkowsky SH. (1989). Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res, 6:40–43.
   PubMed Web of Science ®Google Scholar
• Wei L, Sun P, Nie S, Pan W. (2005). Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Dev Ind Pharm, 31:785–794.
   PubMed Web of Science ®Google Scholar
• Wang XQ, Dai JD, Zhang H, Zhang X, Wang JC, Zhang Q. (2008). Absorption mechanism of cyclosporine A loaded pH-sensitive nanoparticles in rats. J Nanosci Nanotechnol, 8:2422–2431.
   PubMed Web of Science ®Google Scholar
• Rama Prasad YV, Minamimoto T, Yoshikawa Y, Shibata N, Mori S, Matsuura A et al. (2004). In situ intestinal absorption studies on low molecular weight heparin in rats using labrasol as absorption enhancer. Int J Pharm, 271:225–232.
   PubMed Web of Science ®Google Scholar
• Kompella UB, Lee VH. (2001). Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv Drug Deliv Rev, 46:211–245.
   PubMed Web of Science ®Google Scholar
• Pang KS. (2003). Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos, 31:1507–1519.
   PubMed Web of Science ®Google Scholar
• Schulze JD, Peters EE, Vickers AW, Staton JS, Coffin MD, Parsons GE et al. (2005). Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. Int J Pharm, 300:67–75.
   PubMed Web of Science ®Google Scholar